- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
- Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
- Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
- Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
- Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
- Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.292 |
---|---|
High | 0.3077 |
Low | 0.2111 |
Bid | 0.270 |
Offer | 0.2896 |
Previous close | 0.300 |
Average volume | 110.06k |
---|---|
Shares outstanding | 45.76m |
Free float | 36.14m |
P/E (TTM) | -- |
Market cap | 13.73m USD |
EPS (TTM) | -1.93 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 21:00 BST.
More ▼